Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non-Small Cell Lung Cancer
Brief Summary: To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.


Options:
A: Arm Label: IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: Pemetrexed + Carboplatin (AUC 6) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin | Arm Label: IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: IMC-1121B (ramucirumab), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Arm Label: Gemcitabine + Carboplatin (AUC 5) or Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5) | Intervention Type: BIOLOGICAL; Name: IMC-1121B (ramucirumab); Assigned to Arm(s): IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 6); Assigned to Arm(s): IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin, Pemetrexed + Carboplatin (AUC 6) or Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin | Intervention Type: DRUG; Name: Carboplatin (AUC 5); Assigned to Arm(s): Gemcitabine + Carboplatin (AUC 5) or Cisplatin, IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin
B: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): N/A
C: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy
D: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy

Answer: B